This website is intended for U.S. residents only. This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including those under development. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.
An integral component of changing tomorrow is Astellas' commitment to bringing innovative and effective medicines to patients worldwide.
To provide these products and services, Astellas collaborates with health care professionals and health care organizations to drive medical innovation, focus on unmet needs, and educate providers and patients on therapeutic treatments. Astellas believes that the medical and scientific exchange between manufacturers and health care providers is essential to our provision of highly effective pharmaceuticals and contributes to improving the health of patients around the world.
Advancing the field of science is rooted in supporting high-quality, independent medical education and global initiatives designed to improve the quality of medical care. Astellas began posting data related to independent medical education grants and charitable donations in 2010 because the company is dedicated to scientific knowledge, high ethical standards, and reliable, innovative medicines. To learn more about Astellas funding and support, please visit the Corporate Grants and Contributions web page.
Astellas is committed to engaging in appropriate financial relationships with health care professionals and organizations, as reflected in the Astellas Charter for Corporate Conduct. We disclose all relevant corporate information in a timely and appropriate manner; not only to stakeholders, but also to society at large, fulfilling our obligations of corporate accountability. Under the U.S. Physician Payments Sunshine Act, manufacturers of covered drugs, devices, biologicals and medical supplies are required to track and report payments or other transfers of value made to U.S. licensed physicians and U.S. teaching hospitals. The Centers for Medicare and Medicaid Services (CMS) publicly posts this data on an annual basis.